top of page

We are a small private laboratory of biopharmaceutical research located in Slovakia.

​

Deciphering the bioactive profile of secondary metabolites from natural products and exploring the therapeutic usefulness of various TLR agonists and combined approaches are at the core of our permanent research interests associated with in-house pharmaceutical development.​​

​

Our approach to developing modern neuro-immunotherapies across a broad spectrum of non-progressive and progressive neurological and neuropsychiatric disorders centers on the unifying role of sterile inflammation marked by a failure of resolution as a key contributor to disease progression.

Within a milieu of neuroendocrine-immune dysregulation sustained by DAMPs, subclinical exposure to non-cytotoxic PAMPs is emerging as a safe and promising therapeutic paradigm. By integrating PAMP-dependent signaling crosstalk, this strategy reconciles contextual pro-inflammatory and regulatory cues across immune-parenchymal interactions.

Our non-pathogenic, microbial-derived multiple TLR agonist, codenamed Sym9922, potentiates negative feedback signaling during maladaptive inflammatory states, shifting the resulting immune response toward regulatory control.

Broadly, resolving a neuroinflammatory insult or mood disturbance while restoring tissue homeostasis through in situ immune reprogramming is regarded as a physiologically sound strategy for functional recovery.

Compound

Mechanism of action/Modality

Indication

Development stage

Sym9922

Ischemic preconditioning through low-dose induction of TLR hyporeactivity to build tolerance against hypoxia-ischemia

Secondary stroke prevention (post-TIA).

Neuroprotection and modulation of neuroinflammation

Preclinical

Sym9922

Increased hippocampal neurogenesis, antidepressant-like effects (reversal of stress-induced anhedonia), improved cognitive function

Post-stroke and traumatic brain injury recovery.

Slowing or halting neurodegeneration, and enhancing adult neurogenesis in neurodegeneration-related cognitive decline.

Treatment of anhedonia and depressive disorders

Preclinical

VM71224

Modulation of the tumor immune microenvironment.

Induction of Th1 cytotoxic responses

Cancer immunotherapy

Discovery

Helping others regain happiness

"For everyone seeking a healthy, natural lifestyle and sustainable ways to maintain positive mental health and prevent neurological disorders"

- Our value proposition
Terms of Use 
Privacy
Cookie Settings

© 2024 by VISSAN BioLabs

bottom of page